Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Ohio for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Ohio only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Ohio (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Sanaullah Khalid (NPI 1811285562)

Field	Value
Entity Type	Individual
Organization	Sanaullah Khalid
Address	835 Southwestern Run
City	Youngstown
State	OH
ZIP	44514
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 15, 2011

Payer Source	Total Paid
Medicare	$2M
Medicaid	$0

Key Findings

This provider’s billing footprint is effectively single‑payer: lifetime Medicare revenue is $2M while Medicaid billing is listed as none, so operations and revenue are concentrated entirely in the Medicare program. That payer concentration exposes the practice to Medicare policy and reimbursement changes rather than state Medicaid dynamics.

Revenue is highly concentrated in a small set of drug and infusion codes: the precomputed top 3 Medicare codes by revenue account for 86.0% of this provider’s total Medicare revenue, with J9271 (pembrolizumab) alone representing $1.4M or 72.6% of Medicare revenue. The next two contributors are J0897 (denosumab) at $202K (10.1%) and 96413 (chemotherapy administration) at $65.2K (3.3%), underscoring extreme dependence on a few high‑volume infusion services.

The code mix indicates an oncology infusion practice focused on immunotherapy and parenteral cancer therapies: J9271 has 36.2K claims and is the dominant revenue driver, while chemotherapy administration codes such as 96413 (716 claims) and add‑on infusion codes (96417, 96411, 96415) appear throughout the top codes. Frequent use of supportive injectables (J0897 with 11.2K claims, J0881 with 14.8K claims, and J1439 with 24.8K claims) supports a workflow that combines anticancer biologics with bone‑support and iron therapies typical of a hematology/oncology infusion center.

On competitive standing, the provider ranks very highly on key oncology use metrics: J9271 is ranked #50 of 1841 providers nationally (97th percentile) and 96413 is ranked #246 of 7514 (97th percentile), both described as notably above typical national volume for these codes. In contrast, J0897 is ranked #934 of 10057 (91th percentile) and described as typical/unremarkable, indicating the provider is a major national volume outlier for pembrolizumab and chemotherapy administration but more ordinary for some supportive agents.

Several codes are statistical outliers in terms of volume relative to peers, reinforcing an inference of high infusion throughput: J9271 (notably above typical national volume), 96413 (notably above typical national volume), and 96367 (ranked in the 95th percentile and described as notably above typical national volume) all signal unusually large per‑provider infusion activity. Other high‑count codes used for routine E/M and infusion administration appear in elevated percentiles but are described as typical or unremarkable, which suggests the outlier status is concentrated in select oncology drug administrations rather than across all service types.

Operational and contracting implications follow from the concentration: with $1.4M tied to J9271 (72.6% of Medicare revenue) within a $2M Medicare book, payer negotiations, prior authorization performance, and drug acquisition/reimbursement timing for pembrolizumab will materially affect the practice’s financial performance. This concentration creates both leverage in demonstrating specialty volume to payers and vulnerability if utilization patterns or coverage policies for that drug change.

Clinical workflow signals are consistent with ongoing management of active oncology patients: the practice reports 833 claims for 99213 (office E/M) with the code ranked in the 98th percentile and described as notably above typical national volume, indicating frequent established‑patient visits consistent with repeated infusion cycles and follow‑up care. Combined high counts across infusion, add‑on, and E/M codes paint a picture of an established outpatient infusion clinic rather than a pure consultation or inpatient specialty.

The provider has a long NPI tenure (enumerated 2011-07-15, ~15 years ago), which supports an interpretation of an established specialty practice that has maintained high infusion volumes over time. Longevity plus the high national percentiles on key infusion and oncology codes suggests stable clinic operations and an entrenched role in delivering immunotherapy and chemotherapy services to Medicare beneficiaries.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

34 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	36,210	$40	$1.4M
J0897	Injection, denosumab, 1 mg	11,220	$20	$202K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	720	$90	$65.2K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	830	$60	$50.8K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	14,800	$1	$29.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	330	$90	$28.9K
J1439	Injection, ferric carboxymaltose, 1 mg	24,750	$1	$24.8K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	170	$130	$21.4K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	60	$340	$18.8K
99233	The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the…	160	$90	$14.4K

Showing 1–10 of 34

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 34 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Ohio Distribution

Sanaullah Khalid — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Ohio

Full comparison — all codes billed, vs. state median

34 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	2	40	12,100	$40	$603K
J0897	17	230	2,880	$20	$79.5K
J0881	9	20	14,800	$1	$36.6K
J1454	4	10	70	$340	$31.6K
J1439	9	20	20,250	$1	$27.4K
96413	4	210	130	$90	$16.8K
99214	2,732	20,010	100	$70	$11.7K
99233	1,314	5,570	70	$90	$11.2K
J0185	4	20	5,980	$1	$9K
Q0138	2	30	15,300	$1	$8.9K

Showing 1–10 of 34

Related Providers

Other providers that share a Tax Identification Number (TIN) with Sanaullah Khalid, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Alberto Parra	TX	Hematology & Oncology Physician	$1.4M	$0
Talha Riaz	TX	Hematology & Oncology Physician	$1.3M	$0
Nabila Waheed	TX	Radiation Oncology Physician	$939.8K	$0
Zachary Brownlee	TX	Radiation Oncology Physician	$740.9K	$0
Rohan Gupta	TX	Hematology & Oncology Physician	$678.8K	$0
Aaron Laine	TX	Radiation Oncology Physician	$609.5K	$0
Asim Ahmad	TX	Hematology & Oncology Physician	$602.2K	$0
Nicole Bartosh	TX	Medical Oncology Physician	$498.4K	$0
Shadan Mansoor	TX	Hematology & Oncology Physician	$467.4K	$0
Ray Page	TX	Hematology & Oncology Physician	$463.3K	$0

Nearby Providers

Other providers in the same ZIP code as Sanaullah Khalid, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Maxim Healthcare Services, Inc.	OH	Home Health Agency	$0	$22.9M
Knapp Center For Childhood Development	OH	Community/Behavioral Health Agency	$0	$16.6M
Julie Knapp	OH	Clinical Psychologist	$0	$10M
Shc Youngstown Ohio Laboratory Services Company LLC	OH	Clinical Medical Laboratory	$708.9K	$3.4M
Cavalier Mobile Xray Co	OH	Portable X-ray and/or Other Portable Diagnostic Imaging Supplier	$486.5K	$2.5M
Center For Advanced Eye Surgery, Ltd	OH	Ambulatory Surgical Clinic/Center	$1.1M	$221.8K
Tosc, LLC	OH	Ambulatory Surgical Clinic/Center	$1.1M	$9.6K
Amy Awaida	OH	Hematology & Oncology Physician	$414.7K	$0
Nicholas Flebotte	OH	Optometrist	$372.7K	$400
Dean Ball	OH	Diagnostic Radiology Physician	$300.4K	$0

Sanaullah Khalid — Billing Profile & Reimbursement Data

Sign up for Sanaullah Khalid — Billing Profile & Reimbursement Data policy alerts

Sanaullah Khalid — Billing Profile & Reimbursement Data

Sign up for Sanaullah Khalid — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References